A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1

See also
Status	Clinical Trial	Phase
Completed	`NCT04966156` - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT	N/A
Recruiting	`NCT05942885` - Hypnosis: a Path to Appeasement	N/A
Recruiting	`NCT05715047` - Intervention for Fatigue in HCT Recipients	N/A
Recruiting	`NCT05142033` - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed	`NCT06053918` - Research-Action in Hematology From Hospitalization to Home
Recruiting	`NCT05175508` - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS	Phase 2/Phase 3
Not yet recruiting	`NCT04822974` - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS	N/A
Not yet recruiting	`NCT06279585` - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD	N/A
Recruiting	`NCT05753501` - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies	Phase 1
Recruiting	`NCT05481502` - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors	N/A
Not yet recruiting	`NCT04412135` - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Not yet recruiting	`NCT06377059` - Early Detection of Complications During Immunotherapy for Haematological Malignancy	N/A
Completed	`NCT04235153` - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting	`NCT05626764` - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting	`NCT04035447` - Symptom Management for YA Cancer Survivors	N/A
Not yet recruiting	`NCT05602168` - Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance	N/A
Terminated	`NCT03955276` - An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
Recruiting	`NCT03091933` - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)	Phase 1/Phase 2
Withdrawn	`NCT01792882` - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Active, not recruiting	`NCT05493800` - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT	Phase 2

NCT number	NCT00742560
Study type	Interventional
Source	AbbVie
Contact
Status	Completed
Phase	Phase 2
Start date	August 2008
Completion date	October 2016

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms